JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Braun, E. B.
Right arrow Articles by Hogue, C. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Braun, E. B.
Right arrow Articles by Hogue, C. W.
Related Collections
Right arrow Cardiovascular
Right arrow Heart
Right arrow Regional Anesthesia
Right arrow Pharmacology

Anesth Analg 2004;99:36-37
© 2004 International Anesthesia Research Society
doi: 10.1213/01.ANE.0000121349.15880.DC

CARDIOVASCULAR ANESTHESIA

Vasopressin During Spinal Anesthesia in a Patient with Primary Pulmonary Hypertension Treated with Intravenous Epoprostenol

Edward B. Braun, MD, Christopher A. Palin, MBBS FRCA, and Charles W. Hogue, MD

Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri

Address correspondence and reprint requests to Charles Hogue, MD, Campus Box 8054, 660 S. Euclid Avenue, St Louis, MO 63110–1093. Address email to hoguec{at}wustl.edu

Primary pulmonary hypertension (PPH) is a progressive disease with frequent morbidity and mortality, including the risk of cardiac decompensation and death, during general anesthesia. Administration of IV epoprostenol (Flolan) improves symptoms and survival of patients with PPH and thus is an increasingly used long-term treatment for this condition. This therapy is associated with impaired platelet aggregation, which may complicate the perioperative management of patients with PPH. We present a case report of a patient with severe PPH receiving a continuous epoprostenol infusion undergoing skin grafting for a leg ulcer under spinal anesthesia. An IV infusion of vasopressin was given to prevent systemic hypotension resulting from sympathetic blockade while avoiding increases in pulmonary vascular resistance that may have resulted from catecholamine usage.

IMPLICATIONS: Primary pulmonary hypertension (PPH) is a progressively fatal disease that is associated with cardiovascular collapse and death with general anesthesia. We present a patient with PPH who underwent skin grafting under spinal anesthesia while receiving a continuous IV epoprostenol infusion. IV vasopressin was used to avoid systemic hypotension associated with spinal anesthesia.




This article has been cited by other articles:


Home page
 Br J AnaesthHome page
L. C. Price, P. Forrest, V. Sodhi, D. L. Adamson, C. Nelson-Piercy, M. Lucey, and L. S. Howard
Use of vasopressin after Caesarean section in idiopathic pulmonary arterial hypertension
Br. J. Anaesth., October 1, 2007; 99(4): 552 - 555.
[Abstract] [Full Text] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
K. Subramaniam and J.-P. Yared
Management of Pulmonary Hypertension in the Operating Room
Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2007; 11(2): 119 - 136.
[Abstract] [PDF]


Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press
Copyright © 2004 by the International Anesthesia Research Society.